Physician profile
Jason E Rieser
NPI 1922001494
$4,328.38
in general payments reported to CMS, 2019-2025
26 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $295 · 2021: $716 · 2022: $762 · 2023: $748 · 2024: $825 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.37 | 2021-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.10 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $596.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $583.79 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Pfizer INC. | $245.72 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.50 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $155.73 | 2021 | |
| Gilead Sciences, INC. | $116.24 | 2021-2025 | Epclusa |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.80 | 2022 | |
| Dynavax Technologies Corporation | $78.36 | 2023-2025 | Heplisav-B |
| Alexion Pharmaceuticals, INC. | $72.11 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $56.74 | 2021-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $50.79 | 2023-2025 | Vaxneuvance, Varivax, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.46 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.89 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $36.92 | 2020-2024 | Proclaim |
| Exact Sciences Corporation | $28.96 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $27.89 | 2025 | Gemtesa |
| Cranial Technologies, INC | $24.57 | 2025 | Doc Band |
| Esperion Therapeutics, INC. | $23.69 | 2025 | Nexletol |
| Alkermes, INC. | $19.32 | 2023 | Vivitrol |
| Axsome Therapeutics, INC. | $19.23 | 2024 | Auvelity |
| Aquestive Therapeutics, INC. | $18.02 | 2025 | |
| Astellas Pharma US INC | $13.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.06 | 2023 | |
| Allergan, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rieser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.